Momenta taps BioFactura's NS0 cell line tech for biosimilar candidate

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Matej Kastelic
Image: iStock/Matej Kastelic

Related tags: Bristol-myers squibb

Momenta Pharmaceuticals has partnered on the development of an undisclosed biosimilar using BioFactura’s StableFast biomanufacturing platform.

The Frederick, Maryland-based biomanufacturing firm’s StableFast technology generates NS0 cell lines and will be applied to one of Momenta’s biosimilar candidates as part of a deal announced this week.

“We cannot reveal the Momenta development candidate,”​ BioFactura’s CEO Darryl Sampey told Biopharma-Reporter, but “development stage is preclinical/pre-IND and in the product development pathway.”

Momenta’s most advanced biosimilar candidate is M923, a biosimilar of AbbVie’s Humira (adalimumab), which it is hoping to launch in 2018. It’s second most advanced is a version of Bristol-Myers Squibb’s Orencia (abatacept) and is in the preclinical and process development stages.

The firm also has a number of undisclosed pipeline candidates, including six being co-developed with Mylan following a partnership deal signed in January​.

Momenta did not respond to this publication’s request for further information about the deal with BioFactura.

StableFast Platform

The deal gives Momenta the right to obtain an exclusive research and commercial license to StableFast for clinical development and commercial manufacture of the undisclosed.

According to Sampey, the use of his firm’s cell line platform can potentially lower the cost of manufacturing a biosimilar.

“The StableFast Biomanufacturing Platform takes advantage of the NS0 host cell line’s inability to make its own cholesterol which is required for survival,”​ he said.

“We add the gene that codes for an enzyme that allows the cells to make their own cholesterol along with the genes that code for the drug product. This process results in a manufacturing cell line that can survive in cholesterol-free conditions and that produces high yields of the drug product.”

The cholesterol-free nature of the cell lines allow them to be compatible with single-use technologies which, he continued, plays to the high demand for such systems.

“The requirement of added cholesterol in the legacy NS0 platform causes significant problems in manufacturing both in single-use and classic bioreactors. StableFast eliminates these problems and, additionally, enhances the productivity of the drug product thereby reducing cost of manufacturing.”

Accordingly, over a dozen products have so far been manufactured using StableFast, Sampey added.

Related news

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars